Journal of Surgical Research
Volume 157, Issue 1 , Pages e87-e95 , November 2009

Sulindac Prevents Carcinogen-Induced Intrahepatic Cholangiocarcinoma Formation In Vivo

  • Sabrina C. Wentz, M.D.

      Affiliations

    • Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Michele T. Yip-Schneider, Ph.D.

      Affiliations

    • Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana
    • Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Earl A. Gage, M.D.

      Affiliations

    • Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Romil Saxena, M.D.

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • Sunil Badve, M.D.

      Affiliations

    • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
    • ,
  • C. Max Schmidt, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Indiana University School of Medicine, Indianapolis, Indiana
    • Indiana University Cancer Center, Indiana University School of Medicine, Indianapolis, Indiana
    • Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana
    • Walther Oncology Center, Indiana University School of Medicine, Indianapolis, Indiana
    • Richard L. Roudebush VAMC, Indiana University School of Medicine, Indianapolis, Indiana
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Departments of Surgery and Biochemistry, Cancer Research Institute, Molecular Biology, 1044 W Walnut St. R4-039, Indianapolis, IN 46202.

Received 30 June 2008

References 

  1. Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: A true increase?. J Hepatol. 2004;40:472
  2. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis. 2008;12:131
  3. Khan SA, Taylor-Robinson SD, Toledano MB, et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol. 2002;37:806
  4. Gores GJ. Cholangiocarcinoma: Current concepts and insights. Hepatology. 2003;37:961
  5. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115
  6. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis. 2001;5:191
  7. Weizel TM, Graubard BI, El-Serag HB, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based case-control study. Clin Gastroenterol Hepatol. 2007;5:1221
  8. Sirica AE. Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5
  9. Spinella F, Rosano L, Di Castro V, et al. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells. Clin Cancer Res. 2004;10:4670
  10. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002;62:2343
  11. Niho N, Kitamura T, Takahashi M, et al. Suppression of azoxymethane-induced colon cancer development in rats by a cyclooxygenase-1 selective inhibitor, mofezolac. Cancer Sci. 2006;97:1011
  12. Lampiasi N, Fodera D, D'Alessandro N, et al. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med. 2006;17:245
  13. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res. 2005;65:3735
  14. Chariyalertsak S, Sirikulchayanonta V, Mayer D, et al. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut. 2001;48:80
  15. Nzeako UC, Guicciardi ME, Yoon JH, et al. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35:552
  16. Kim HJ, Lee KT, Kim EK, et al. Expression of cyclooxygenase-2 in cholangiocarcinoma: Correlation with clinicopathological features and prognosis. J Gastroenterol Hepatol. 2004;19:582
  17. Sirica AE, Lai GH, Zhang Z. Biliary cancer growth factor pathways, cyclo-oxygenase-2 and potential therapeutic strategies. J Gastroenterol Hepatol. 2001;16:363
  18. Wong M, Chowienczyk P, Kirkham B. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Aust Fam Physician. 2005;34:945
  19. Davies NM, Jamali F. COX-2 selective inhibitors cardiac toxicity: Getting to the heart of the matter. J Pharm Pharm Sci. 2004;7:332
  20. Fu SL, Wu YL, Zhang YP, et al. Anti-cancer effects of COX-2 inhibitors and their correlation with angiogenesis and invasion in gastric cancer. World J Gastroenterol. 2004;10:1971
  21. Berman KS, Verma UN, Harburg G, et al. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin Cancer Res. 2002;8:354
  22. Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Mol Cancer Ther. 2005;4:587
  23. Sun BC, Zhao XL, Zhang SW, et al. Sulindac induces apoptosis and protects against colon carcinoma in mice. World J Gastroenterol. 2005;11:2822
  24. Takada Y, Bhardwaj A, Potdar P, et al. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. 2004;23:9247
  25. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. Faseb J. 2001;15:2057
  26. Wieser F, Vigne JL, Ryan I, et al. Sulindac suppresses nuclear factor-κB activation and RANTES gene and protein expression in endometrial stromal cells from women with endometriosis. J Clin Endocrinol Metab. 2005;90:6441
  27. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem. 1999;274:27307
  28. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461
  29. Qiao L, Zhang H, Yu J, et al. Constitutive activation of NF-κB in human hepatocellular carcinoma: Evidence of a cytoprotective role. Hum Gene Ther. 2006;17:280
  30. Karin M. Nuclear factor-κB in cancer development and progression. Nature. 2006;441:431
  31. Nishimura D, Ishikawa H, Matsumoto K, Shibata H, Motoyoshi Y, Fukuta M, et al DHMEQ, a novel NF-κB nhibitor, induces apoptosis and cell-cycle arrest in human hepatoma cells. Int J Oncol. 2006;29:713
  32. Egami H, Takiyama Y, Cano M, Houser WH, Pour PM. Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens. Carcinogenesis. 1989;10:861
  33. Mizumoto K, Tsutsumi M, Denda A, et al. Rapid production of pancreatic carcinoma by initiation with N-nitroso-bis(2-oxopropyl)amine and repeated augmentation pressure in hamsters. J Natl Cancer Inst. 1988;80:1564
  34. Endl E, Gerdes J. The Ki-67 protein: Fascinating forms and an unknown function. Exp Cell Res. 2000;257:231
  35. Brown DC, Gatter KC. Ki67 protein: The immaculate deception?. Histopathology. 2002;40:2
  36. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol. 2000;182:311
  37. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353
  38. Yamanaka S, Tomioka T, Tajima Y, etal O. K-ras gene mutations in intrahepatic bile duct tumors of Syrian golden hamsters. J Surg Oncol. 1997;66:97
  39. Nakanuma Y, Harada K, Ishikawa A, et al. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2003;10:265
  40. Arsura M, Cavin LG. Nuclear factor-κB and liver carcinogenesis. Cancer Lett. 2005;229:157
  41. Chen RF, Li ZH, Kong XH, et al. Effect of mutated IκBα transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World J Gastroenterol. 2005;11:726
  42. Liu X, Zou S, Qiu F. Expression of nuclear factor-κB in hepatitis C virus core gene transfected cholangiocarcinoma cells. Chin Med J (Engl). 2002;115:998
  43. Pinlaor S, Hiraku Y, Yongvanit P, et al. iNOS-dependent DNA damage via NF-κB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int J Cancer. 2006;119:1067
  44. Marquez-Rosado L, Trejo-Solis MC, Garcia-Cuellar CM, et al. Celecoxib, a cyclooxygenase-2 inhibitor, prevents induction of liver preneoplastic lesions in rats. J Hepatol. 2005;43:653
  45. Ciolino HP, Bass SE, MacDonald CJ, et al. Sulindac and its metabolites induce carcinogen metabolizing enzymes in human colon cancer cells. Int J Cancer. 2007;122:990
  46. Tsuchida A, Itoi T, Kasuya K, et al. Inhibitory effect of meloxicam, a cyclooxygenase-2 inhibitor, on N-nitrosobis (2-oxopropyl) amine induced biliary carcinogenesis in Syrian hamsters. Carcinogenesis. 2005;26:1922
  47. Tsuneoka N, Tajima Y, Kitazato A, et al. Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters. Carcinogenesis. 2005;26:465

PII: S0022-4804(08)00649-5

doi: 10.1016/j.jss.2008.10.006

Journal of Surgical Research
Volume 157, Issue 1 , Pages e87-e95 , November 2009

Article Tools

* Image Usage & Resolution